Skip to content

Discerning Data

  • About Us
  • Additional Resources
  • Contact Us

DISCERNING DATA

A Faegre Drinker Blog Covering the Latest in Privacy, Cybersecurity and Data Strategy

  • Privacy
  • Cybersecurity
  • Data Strategy
  • Disruptionware

FDA Expands Big Data Use with Sentinel System

Share

The U.S. Food and Drug Administration (FDA) is increasing its capability to harness the power of big data – or more specifically of the “real world evidence” (RWE) – to assess the safety of medical products that are approved for the U.S. market. To that end, FDA is expanding its Sentinel System so that by the end of 2023 it would represent “a transformative, multi-purpose national data and scientific resource center for evidence generation that a wide array of stakeholders use to inform all aspects of healthcare decision making,” according to the recently released Sentinel System Five-Year Strategy.

The Sentinel Initiative was first started about 10 years ago, to fulfill the legislative mandate under section 905 of the FDA Amendments Act of 2007. The main goal was to establish a computerized safety surveillance system for drugs on the market, in order to augment the existing FDA post-market surveillance activities.

The full implementation of the Sentinel System was launched in 2016. Its distributed data system integrates data from 18 partner institutions, including Aetna, Blue Cross Blue Shield of Massachusetts, Duke University, Kaiser Permanente, HCA, and Optum, among others, while preserving patient privacy. The system allows FDA to evaluate safety risk signals from RWE more efficiently than before; and if such evidence is deemed sufficient to address a potential safety risk, it may even obviate the need for biopharmaceutical or medical-device companies to conduct post-market safety studies.

FDA continues to evolve the tools and methods used by the Sentinel System to identify and evaluate the risks. Important insights can be gained by combining data from different sources (e.g., distributed health networks), by refining the data analysis methods. For example, linking mother and infant data enables evaluation of the impact of fetal exposures to medications. As an example of the method-based advance, the use of machine learning and natural language processing created a way to identify instances of serious allergic reactions to medications, e.g., anaphylaxis.

At the same time, the agency still continues to utilize traditional sources of potential safety signals, such as reports generated by medical product sponsors, patients or health care providers; medical literature and lay media; clinical trials; and Adverse Event Reporting System. In contrast, Sentinel System could not only integrate the input from different sources, but actively detect potential signals, by analyzing health outcomes from large populations in a large set of real-world scenarios.

In the next five years, FDA plans to expand data sources and linkages, test and improve its algorithms, increase data diversity, build up data-mining capabilities, leverage advances in data science and in safety-signal detection, broaden the Sentinel System’s user base, and encourage innovation and collaboration. For example, conceptually, FDA envisions eventual open access to the Sentinel System by patients, providers, academia, industry, other U.S. agencies, payors, and non-U.S. health authorities.

Such a broad-spanning system, once implemented, may enable qualitatively new improvements in health care. On the other hand, the challenges in designing and managing the system will mount with every additional layer of complexity. Along the way, therefore, significant investment in time, resources, and public engagement will be needed both to develop, test and maintain the sophistical technical solutions, and to ensure appropriate privacy and security protections.

The material contained in this communication is informational, general in nature and does not constitute legal advice. The material contained in this communication should not be relied upon or used without consulting a lawyer to consider your specific circumstances. This communication was published on the date specified and may not include any changes in the topics, laws, rules or regulations covered. Receipt of this communication does not establish an attorney-client relationship. In some jurisdictions, this communication may be considered attorney advertising.

Receive Email Alerts to New Articles

SUBSCRIBE

February 5, 2019
Written by: Svetlana Lyapustina
Category: Health Care, Pharma/Life Sciences
Tags: Big Data, data mining, FDA, machine learning, patient privacy

Post navigation

Previous Previous post: England’s National Health Service Long Term Plan Envisions NHS-wide Adoption of Digital Tools
Next Next post: Another Big Blockchain Initiative Announced in Health Care Insurance Industry

Search the Blog

Sign Up for Email Alerts

PODCASTS

Faegre Drinker on Law and Technology

©2023 Faegre Drinker Biddle & Reath LLP. All Rights Reserved. Lawyer Advertising.

  • About Us
  • Additional Resources
  • Contact Us
We use cookies to improve your experience with our website. By browsing our site, you are agreeing to the use of cookies. For more information about how we use cookies, please review our privacy policy and cookie policy. OK
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT